^
Association details:
| Biomarker: | HER-2 L755S |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Pozenveo (poziotinib) (HER2 inhibitor, HER4 inhibitor, pan-EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Poziotinib inhibits HER2 mutant-driven therapeutic resistance and multi-organ metastasis in breast cancer
Published date:
06/23/2022
Excerpt:
The most highly recurrent HER2 mutant, L755S, was particularly resistant to neratinib but sensitive to the pan-HER TKI poziotinib, alone or in combination with fulvestrant....Similar therapeutic effects of poziotinib were observed in both an engineered HER2L755S MCF7 model and a patient-derived xenograft harboring a HER2G778_P780dup mutation. Overall, these findings support the need for clinical evaluation of poziotinib for the treatment of HER2 mutant metastatic breast cancer.
Secondary therapy:
fulvestrant
DOI:
10.1158/0008-5472.CAN-21-3106
Source:
Title:
Poziotinib inhibits HER2 mutant-driven therapeutic resistance and multi-organ metastasis in breast cancer
Published date:
06/23/2022
Excerpt:
The most highly recurrent HER2 mutant, L755S, was particularly resistant to neratinib but sensitive to the pan-HER TKI poziotinib, alone or in combination with fulvestrant....Similar therapeutic effects of poziotinib were observed in both an engineered HER2L755S MCF7 model and a patient-derived xenograft harboring a HER2G778_P780dup mutation. Overall, these findings support the need for clinical evaluation of poziotinib for the treatment of HER2 mutant metastatic breast cancer.
DOI:
10.1158/0008-5472.CAN-21-3106
